Archives of Psychiatry Research
December 29, 2025
Darko Vlahović, D. Vlahovic
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is a serotonergic psychedelic with preferential agonism at 5-HT1A receptors and rapid pharmacokinetics, allowing for a brief, supervised in-clinic administration. Preclinical studies demonstrate that 5-MeO-DMT...
Revista Multidisciplinar do Nordeste Mineiro
December 28, 2025
Marcos Lorran Paranhos Leão, Estácio Amaro Da Silva Júnior
A ayahuasca é uma bebida psicoativa de origem amazônica, tradicionalmente utilizada por povos indígenas e por religiões de matriz brasileira, cuja composição combina plantas ricas em N,N-dimetiltriptamina (DMT) e alcaloides β-carbolínicos. Nas últimas décadas, observa-se crescente interesse científico acerca de seus potenciais efeitos terapêuticos, especialmente no campo da saúde mental, bem...
Journal of Psychopharmacology
December 26, 2025
Kurt Stocker, Matthias Hartmann, Yasmin Schmid et al.
5 citations
The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC...
Journal of Neuroscience
December 19, 2025
Nicolas G. Glynos, Emma R. Huels, Trent Groenhout et al.
11 citations
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that is being investigated for the treatment of psychiatric disorders. Although the neurophysiological effects of DMT in humans are well characterized, similar studies in animal models and data on the neurochemical effects of DMT are generally lacking, which are critical for a mechanistic understanding. Here, we combined behavioral...
ACS Medicinal Chemistry Letters
December 16, 2025
Anna C. Renner, Robert B. Kargbo
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches...
Neuroscience & Biobehavioral Reviews
December 16, 2025
Rivka Vollebregt, A. J. Storm, Paul J. Lucassen et al.
3 citations
Classical psychedelics, like lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and psilocybin, can alter perception, emotion, and cognition, and have shown promise as 're-purposed' treatments for some psychiatric disorders. Recent trials have, e.g., demonstrated rapid and sustained symptom relief in treatment-resistant depression. While promising as a treatment, the...
Zenodo (CERN European Organization for Nuclear Research)
December 15, 2025
preprint
Encounters with seemingly autonomous non-human entities are among the most striking and consistently reported phenomena associated with psychedelic states, particularly those induced by N,N-dimethyltryptamine (DMT). In contemporary discourse, these encounters are frequently described through the archetype of the “machine elf,” a term popularized by ethnobotanist Terence McKenna in the late...
Addiction
December 10, 2025
John Marsden, Michael Kelleher, Fiona Dunbar et al.
2 citations
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT). Design Open‐label,...
Advanced Neurology
December 4, 2025
Taslim Uddin, Sharmin Akter, Kaustabh Ghosh
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disorders. Psilocybin, lysergic acid diethylamide, N,N-dimethyltryptamine, and ketamine are substances that mainly affect the serotonergic and glutamatergic systems. They induce rapid synaptogenesis, dendritic remodeling, and changes in functional...
Journal of Psychiatric Research
November 26, 2025
Michael van Ameringen, Vidhi Patel, Beth Patterson et al.
The etiology of OCD is complex and appears to involve multiple biological pathways. Imbalances in central serotonin, dopamine, and glutamate activities are widely thought to play a causative role. Despite strong evidence supporting first-line OCD pharmacotherapies, approximately 40-60 % of OCD patients remain unresponsive and are considered treatment resistant (TR). Although a range of agents...